Revir Therapeutics is a biotechnology company that develops mRNA-modifying small molecules to treat Huntington's Disease and other neurogenetic disorders.

Revir Therapeutics

ReviR Therapeutics is a research and development company whose mission is to harness advanced technologies, machine learning/AI, and the inherent biology embedded within RNA to develop novel medicines to treat human disease.  Our AI-based platform allows us to expand beyond the protein-based target space to reach a large number of known disease targets previously considered “undruggable”

Strategies
* Invent and build technologies to unlock first-in-class medicines for the treatment of cancer, rare genetic disorders, and infectious diseases
* Decipher disease relevant structural and functional RNA motifs by integrating human genetic data, functional genomics, and AI 
* Integrate Machine Learning tools and advanced the mechanistic understanding of the RNA life cycle at scale in order to deliver transformative therapies for millions of patients 


Shunwei Capital

Sky9 Capital

5Y Capital

Tiantu Capital

CDH Investments

ReviR Therapeutics

We are excited to announce that CMT Research Foundation will sponsor ReviR Therapeutics to develop innovative splice-modulating therapies to treat Charcot Marie Tooth disease type 1A (CMT1A).  https://lnkd.in/gh_edswV
#CMT1A #Splicing #ReviRTherapeutics #CMTRF 
#BiotechNews #TherapeuticDevelopment

A step forward for Huntington's Disease patients today! PTC Therapeutics, Inc. announced 12 month interim data from their ongoing Phase 2 clinical trial of PTC518, a small molecule splicing modulator: evidence of being safe, tolerable, with meaningful clinical benefit: https://lnkd.in/g7NUvxkj

We are pleased to announce a significant step forward for ReviR's splicing modulators for #oncology with Asieris Pharmaceuticals! Shared passion towards cures, driven by innovation #collaboration #vision #drugdiscovery #RNA

https://lnkd.in/g6_UWbDn

We've just wrapped up an invigorating summer internship program at ReviR Therapeutics. Here's a glimpse into the experiences of our remarkable interns.

A Huge Thank You to ReviR’s Scientific Advisory Board!
We want to take a moment to express our sincere gratitude to the incredible members of ReviR’s Scientific Advisory Board.
Your collective feedback, experience, and guidance have been invaluable in shaping our direction as we continue to develop RNA modulating small molecules that are CNS penetrant and orally delivered. Your insights during our recent meeting at our South San Francisco HQ were particularly insightful and will be instrumental in helping us deliver disease modulating therapies to the patients who suffer from neurogenetic diseases, such as Huntington’s Disease. 
[SAB Members Lynne Maquat Ph.D., David Dornan Ph.D.,
Brian Safina Ph.D., Irina Antonijevic MD Ph.D., Elisabetta Morini Ph.D., Julio Medina Ph.D.].


We look forward to continuing to learn from you all and working together to achieve breakthrough therapies for patients who need them most. [ReviR members here. Not pictured Sarah Burnett, Zenia Llamas]

Metric
Company Name	Revir Therapeutics
Symbol
MSH ID	COM:REVIRTX
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	US
Stage
Employee Count	24
Website	revirtx.com
LinkedIn	revir-therapeutics
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

REVI

COM:REVIRTX

Revir Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue